Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jayesh Desai

Showing results (111-120 of 179) with videos related to

Pageof 18
Sort By:
Cancer Medicine|May 19, 2025
Trends in Practice Patterns and Clinical Outcomes for Desmoid Tumors: A Large Single-Institutional Australian CohortJoseph Sia, Stephanie Tan, Narayan Mohanakrishnan, et al.
Cancer Chemotherapy and Pharmacology|October 8, 2025
A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation resultsJayesh Desai, Sanjeev Deva, Bo Gao, et al.
The Lancet. Oncology|July 24, 2017
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 studyMichael J Overman, Ray McDermott, Joseph L Leach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomasJohn V Heymach, Jayesh Desai, Judith Manola, et al.
Internal Medicine Journal|April 3, 2018
Exploring the feasibility and utility of exome-scale tumour sequencing in a clinical settingBelinda Lee, Ben Tran, Arthur L Hsu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2008
DNA copy-number alterations underlie gene expression differences between microsatellite stable and unstable colorectal cancersRobert N Jorissen, Lara Lipton, Peter Gibbs, et al.
International Journal of Surgical Pathology|January 15, 2020
A Malignant Neoplasm From the Jejunum With a <i>MALAT1-GLI1</i> Fusion and 26-Year Survival HistoryOwen William John Prall, Christopher Robert Edward McEvoy, David John Byrne, et al.
Acta Orthopaedica|May 12, 2021
Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trialMichiel Van De Sande, William D Tap, Heather L Gelhorn, et al.
Clinical Orthopaedics and Related Research|August 24, 2022
Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVENJohn H Healey, William D Tap, Heather L Gelhorn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2009
Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal CancerRobert N Jorissen, Peter Gibbs, Michael Christie, et al.
Pageof 18

Showing results (111-120 of 179) with videos related to

Sort By:
Pageof 18
Cancer Medicine|May 19, 2025
Trends in Practice Patterns and Clinical Outcomes for Desmoid Tumors: A Large Single-Institutional Australian CohortJoseph Sia, Stephanie Tan, Narayan Mohanakrishnan, et al.
Cancer Chemotherapy and Pharmacology|October 8, 2025
A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation resultsJayesh Desai, Sanjeev Deva, Bo Gao, et al.
The Lancet. Oncology|July 24, 2017
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 studyMichael J Overman, Ray McDermott, Joseph L Leach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomasJohn V Heymach, Jayesh Desai, Judith Manola, et al.
Internal Medicine Journal|April 3, 2018
Exploring the feasibility and utility of exome-scale tumour sequencing in a clinical settingBelinda Lee, Ben Tran, Arthur L Hsu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2008
DNA copy-number alterations underlie gene expression differences between microsatellite stable and unstable colorectal cancersRobert N Jorissen, Lara Lipton, Peter Gibbs, et al.
International Journal of Surgical Pathology|January 15, 2020
A Malignant Neoplasm From the Jejunum With a <i>MALAT1-GLI1</i> Fusion and 26-Year Survival HistoryOwen William John Prall, Christopher Robert Edward McEvoy, David John Byrne, et al.
Acta Orthopaedica|May 12, 2021
Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trialMichiel Van De Sande, William D Tap, Heather L Gelhorn, et al.
Clinical Orthopaedics and Related Research|August 24, 2022
Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVENJohn H Healey, William D Tap, Heather L Gelhorn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2009
Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal CancerRobert N Jorissen, Peter Gibbs, Michael Christie, et al.
Pageof 18